Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Curtin University · Institut Gustave Roussy · +27 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
561
total citations
- FWCI
- 35.06
- Percentile
- 100%
- References
- 42
Citations per year
Authors
30Topics & keywords
Topics
Keywords
- Neratinib
- Medicine
- Trastuzumab
- Internal medicine
- Breast cancer
- Oncology
- Placebo
- Regimen
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.